NPPB and breast carcinoma: In a study by Ky et al., 78 patients with breast cancer undergoing doxorubicin and trastuzumab therapy received a baseline evaluation with 8 different biomarkers: hsTnI, hsCRP, NT-proBNP, GDF-15, MPO, PlGF, sFlt-1, and Gal-3 (156).